Yisaipu(®) Provide AS Patients With an Economical Therapeutic Option While Original Biologicals are More Advantageous in the COVID-19 Epidemic Situation

Objectives: Anti-tumor necrosis factor (TNF) agents have been regarded as the most effective treatment for ankylosing spondylitis (AS) so far. However, economic factors limited the prescription of original biologicals in China. Yisaipu(®) is a biosimilar for etanercept as pre fill syringes (PFS), wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Hongjuan, Wang, Yuanqiong, Wang, Xiuwen, Wu, Xin, Zhou, Ling, Lin, Li, Sheng, Rong, Tian, Haoran, Li, Ting, Xu, Huji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450409/
https://www.ncbi.nlm.nih.gov/pubmed/34552481
http://dx.doi.org/10.3389/fphar.2021.692768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450409/
https://www.ncbi.nlm.nih.gov/pubmed/34552481
http://dx.doi.org/10.3389/fphar.2021.692768

Ejemplares similares